<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525768</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-cavernoma-EGV</org_study_id>
    <nct_id>NCT04525768</nct_id>
  </id_info>
  <brief_title>Gastroesophageal Varices in Cavernoma</brief_title>
  <official_title>Characteristic of Patients With Gastroesophageal Varices and Portal Cavernoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia,&#xD;
      and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life,&#xD;
      morbidity, and mortality of MPN patients mainly depend on disease-related symptoms,&#xD;
      thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has&#xD;
      a prominent role in vascular risk and MPN-associated gastroesophageal varices. Portal vein&#xD;
      thrombosis and portal cavernoma frequently occur in the MPN population and the management of&#xD;
      gastroesophageal varices in these patients are sometimes technically difficult. The aim of&#xD;
      this study is to investigate the the characteristics of patients with gastroesophageal&#xD;
      varices and portal caver cavernoma with or without JAK2 mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>History of variceal bleeding</measure>
    <time_frame>1 day (the same time as diagnosis)</time_frame>
    <description>Have a history of the occurrence of gastroesophageal variceal bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year death rate</measure>
    <time_frame>1 year</time_frame>
    <description>1-year death rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of portal hypertension</measure>
    <time_frame>1 year</time_frame>
    <description>The concurrence of complications of portal hypertension (ascites, infections, variceal bleeding, et al)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gastroesophageal Varices</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Portal Caver Cavernoma</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>JAK2 mutation Group</arm_group_label>
    <description>Patients with portal caver cavernoma and gastroesophageal varices and JAK2 Mutation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Portal caver cavernoma Group</arm_group_label>
    <description>Patients with portal caver cavernoma and gastroesophageal varices without JAK2 Mutation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>JAK2 mutation test</intervention_name>
    <description>Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test</description>
    <arm_group_label>JAK2 mutation Group</arm_group_label>
    <arm_group_label>Portal caver cavernoma Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who diagnosed with portal cavernoma and gastric and/or esophageal varices and&#xD;
        underwent JAK2 mutation test.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female patients aged 18-75&#xD;
&#xD;
          -  diagnosed as portal hypertension and portal cavernoma by contrast-enhanced computed&#xD;
             tomography&#xD;
&#xD;
          -  underwent JAK2 mutation test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  combined known etiologies of chronic liver disease, including hepatitis, primary&#xD;
             biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease.&#xD;
&#xD;
          -  other factors judged by the investigator that may affect the safety of the subject or&#xD;
             the compliance of the trial. Such as serious illnesses (including mental illness) that&#xD;
             require combined treatment, serious laboratory abnormalities, or other family or&#xD;
             social factors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoquan HUANG, M.D.</last_name>
      <phone>+86-18801733835</phone>
      <email>huangxiaoquan1010@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Reilly CR, Babushok DV, Martin K, Spivak JL, Streiff M, Bahirwani R, Mondschein J, Stein B, Moliterno A, Hexner EO. Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension. Am J Hematol. 2017 Sep;92(9):909-914. doi: 10.1002/ajh.24798. Epub 2017 Jul 26.</citation>
    <PMID>28543980</PMID>
  </results_reference>
  <results_reference>
    <citation>Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):e1-5. doi: 10.1016/j.clml.2014.04.004. Epub 2014 Jun 11.</citation>
    <PMID>25027569</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 23, 2020</last_update_submitted>
  <last_update_submitted_qc>August 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>XiaoquanHUANG</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>portal hypertension</keyword>
  <keyword>gastroesophageal varices</keyword>
  <keyword>jak2 mutation</keyword>
  <keyword>myeloproliferative Neoplasm</keyword>
  <keyword>portal caver cavernoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma, Cavernous</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

